Charles River Laboratories International (NYSE:CRL) updated its second quarter 2021 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.370- for the period, compared to the Thomson Reuters consensus estimate of $2.130. The company issued revenue guidance of $887.36 million-$887.36 million, compared to the consensus revenue estimate of $830.13 million.Charles River Laboratories International also updated its FY 2021 guidance to 9.750-10.000 EPS.

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Charles River Laboratories International from $280.00 to $350.00 and gave the company an overweight rating in a research report on Thursday, February 25th. Deutsche Bank Aktiengesellschaft lifted their price objective on Charles River Laboratories International from $250.00 to $334.00 and gave the stock a buy rating in a research report on Thursday, February 25th. Zacks Investment Research downgraded Charles River Laboratories International from a buy rating to a hold rating in a research report on Monday, April 19th. Truist lifted their price objective on Charles River Laboratories International from $256.00 to $324.00 in a research report on Thursday, February 18th. Finally, Credit Suisse Group lifted their price objective on Charles River Laboratories International from $259.00 to $301.00 and gave the stock a neutral rating in a research report on Thursday, February 18th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $260.80.

Shares of NYSE CRL traded up $7.01 during trading on Tuesday, hitting $338.96. 652,947 shares of the company traded hands, compared to its average volume of 321,532. Charles River Laboratories International has a 1 year low of $139.76 and a 1 year high of $343.47. The company has a 50-day moving average price of $307.12 and a 200-day moving average price of $269.37. The firm has a market capitalization of $17.02 billion, a P/E ratio of 56.49, a P/E/G ratio of 2.19 and a beta of 1.12. The company has a quick ratio of 1.22, a current ratio of 1.45 and a debt-to-equity ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Tuesday, May 4th. The medical research company reported $2.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.19 by $0.34. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%. The company had revenue of $824.60 million during the quarter, compared to analysts’ expectations of $798.52 million. During the same period in the previous year, the company earned $1.84 EPS. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. Research analysts predict that Charles River Laboratories International will post 7.87 EPS for the current fiscal year.

In related news, VP Birgit Girshick sold 1,675 shares of the company’s stock in a transaction on Friday, February 19th. The shares were sold at an average price of $293.92, for a total transaction of $492,316.00. Following the completion of the sale, the vice president now directly owns 31,680 shares of the company’s stock, valued at approximately $9,311,385.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Michael Gunnar Knell sold 410 shares of the business’s stock in a transaction on Friday, February 19th. The stock was sold at an average price of $290.99, for a total transaction of $119,305.90. Following the completion of the transaction, the chief accounting officer now owns 4,198 shares in the company, valued at approximately $1,221,576.02. The disclosure for this sale can be found here. Insiders have sold a total of 111,363 shares of company stock valued at $32,201,105 over the last three months. Corporate insiders own 1.90% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Understanding the two types of arbitrage

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.